Marco Meglio

Using several large-scale cohorts, findings showed that cumulative incidence of Alzheimer disease grows faster with age in R145C variant carriers compared with noncarriers, contradicting prior research results.

Although 57% and 50% of patients with migraine reported being diagnosed with an anxiety or depressive disorders, respectively, healthcare professional estimated these conditions occurred in just 29% and 30% of patients, respectively.

Across the cohort, 11.6% of patients had impairments in memory, attention, and executive function; however, cognitive status was influenced by severity of anosmia, or loss of taste and smell.

Non-White participants over 90 years of age who reported a mean of 4 discrimination experiences had significantly worse baseline semantic memory compared with those who reported little/no discrimination.

As hospitalizations remain high throughout the COVID-19 pandemic, new data suggests that ICU hospitalization is associated with increased risk of Alzheimer disease and all-type dementia.

The study, expected to begin enrollment in May 2023, will evaluate whether cognitive behavioral therapy delivered by telehealth reduces headache days and disability from migraine compared with CBT plus a preventive medication.

In addition to reduced times to treatment, implementation of field stroke triage led to significantly lower rates of disability for both the entire cohort and those independent at baseline among those with large vessel occlusions.

Findings showed that, although risk for serious fall injury was not mitigated by insomnia diagnosis, individuals with active insomnia taking prescribed hypnotic medication may be a particularly high-risk subgroup.

Consistent with previously reported findings, Hispanic pregnant women reported better subjective sleep quality throughout all trimesters compared with non-Hispanic White participants.

Despite recent technological advancements, fewer participants underwent polysomnography and medical grade actigraphy, with minimal adoption of non-PSG electroencephalograms.

The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided context on the influence that genetics will have in drug development for Alzheimer disease in the coming years.

Using a backward logistic regression model, lower functional capacity between the default-mode network and ventral attention network accurately predicted response to cognitive rehabilitation among a cohort of patients with MS.

In addition to reductions of SOD1 protein, earlier start tofersen demonstrated positive effects in clinical function, respiratory function, muscle strength, and quality of life in patients with SOD1 ALS.

At year 5, significantly lower annualized change in EDSS score, lower incidence of confirmed disability worsening, and lower annualized change in FSS pyramidal function were identified in the early initiated treatment group.

Data from a cohort of more than 111,000 women showed that presence of endometriosis increased stroke risk by 34%.

The median time to seizure relapse following antiseizure medication discontinuation was 8 months, although 16.7% of the cohort had relapse occur just 1 month after baseline.

For amyloid positive cognitively unimpaired individuals, the best predicting compositive measure included gender, and changes in ADAS delayed recall, MMSE, SDMT, and Trailmaking Test B.

For most of the individuals assessed, the rate of improvement was modulated by practice frequency, with significantly greater improvement over time in those who practice 3 to 5 days per week than those who completed 1 day of sessions per week.

In previous clinical studies, patients with AADC deficiency treated with the recombinant AAV2-based gene therapy achieved motor milestones, including head control and unassisted sitting.

As previous literature has suggested a link between NAFLD and cognitive dysfunction, new findings showed that the disease was associated with a 38% higher rate of dementia.

Treatment with CNM-Au8 was well-tolerated, with no new safety signals, and decreased the risk of death by 70% compared with placebo on unadjusted Kaplan-Meier analyses.

Findings showed between a 2.4- to 5-fold increased risk of autism spectrum disorder and intellectual disability in children with prenatal exposure to valproate, and similar findings for those exposed to topiramate.

As scientific researchers continue to uncover new genetic links to amyotrophic lateral sclerosis, the rise of gene therapies to treat the neuromuscular disease will remain a development to watch in the coming years.

The vice president of clinical development at Biohaven provided insight on a new phase 3 study assessing a muscle-targeted agent as an adjunct therapy to currently approved spinal muscular atrophy medications.

Over a year treatment period, patients maintained their subscale scores assessing medication effects, energy and fatigue, and cognition, all of which might be expected to be sensitive to a new treatment.

Using rigorous cell-based assays, cerebrospinal fluid GFAP levels were significantly lower in double-seronegative NMOSD than AQP4-positive NMOSD but did not differ between those with MOGAD or other neurological diseases.

The double-blind, placebo-controlled, randomized trial will evaluate CT1812, a small molecule therapeutic designed to address the dual assault from α-synuclein and amyloid-ß oligomers in patients with dementia with Lewy bodies.

Previously used to treat conditions such as temporal lobe epilepsy and focal impaired awareness, the FDA approved a new oral suspension of zonisamide, an antiseizure medication on the market for over 2 decades.

Neuropathic pain and constipation coexisted in 43.5% of the survey participants, and approximately one-third of patients with both symptoms reported a possible link between the two.

Between AQP4-IgG-positive and negative patients with NMOSD, there were no significant differences in cognitive performance, despite having similar demographic and clinical characteristics.